Thiazolidinediones and Glucagon‐Like Peptide‐1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study

BACKGROUND AND AIMS: Thiazolidinediones (TZDs) and glucagon‐like peptide‐1 (GLP‐1) receptor agonists are potential pharmacological treatment options for patients at risk of NAFLD. Therefore, we examined the association between the risk of NAFLD and the use of TZDs and GLP‐1 receptor agonists compare...

Descripción completa

Detalles Bibliográficos
Autores principales: van Dalem, Judith, Driessen, Johanna H. M., Burden, Andrea M., Stehouwer, Coen D. A., Klungel, Olaf H., de Vries, Frank, Brouwers, Martijn C. G. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596626/
https://www.ncbi.nlm.nih.gov/pubmed/34129693
http://dx.doi.org/10.1002/hep.32012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596626/
https://www.ncbi.nlm.nih.gov/pubmed/34129693
http://dx.doi.org/10.1002/hep.32012

Ejemplares similares